Screening and Prevention - A drug that prevents osteoporosis may cut a woman's risk of breast cancer in half

	Empire Front Page
	Local News
	Opinion
	Letters To The Editor
	Neighbors
	State & Regional News
	Obituaries
	Weather
	Business News
	Archives
	Alaska AP Wire
	National AP Wire
	Health

	Local Sports
	Empire Outdoors

	Permanent Fund 2004
	Election Coverage 2004
	Salmon Derby
	Celebration 2004
	This Week
	SoutheastAlaskaHomes
	Juneau Brides
	Alaska Legislature
	Juneau Guide
	Special Sections Archive

	Food Challenge!
	Submit "Around Town" Event
	Calendar
	Books
	Slideshows
	Message Board
	TV Week
	Movie Listings
	Juneau History
	Poll Results

	Classifieds
	Email Newsletter
	Net Marketplace
	Subscribe
	Jobs At The Empire
	Open Carrier Routes
	Local Maps
	Advertising
	Contact Us

Statewide Weather

Breast Cancer Screening and Prevention

A drug that prevents osteoporosis may cut a woman's risk of breast cancer in half

The initial results of a study comparing the drugs tamoxifen, a drug taken to prevent breast cancer, and raloxifene, a drug used to treat and prevent osteoporosis, has shown that both work equally well in reducing a woman's risk of breast cancer. In a study conducted by the National Cancer Institute, which included almost 20,000 women at an average age of 58, researchers found that both tamoxifen and raloxifene cut a woman's risk of breast cancer in half. However, tamoxifen has been linked to serious side effects, raising the risk of life-threatening blood clots and uterine cancer. On the other hand, the researchers discovered that the women taking raloxifene had 36 percent fewer uterine cancers and 29 percent fewer blood clots. Since many women at high risk for breast cancer refuse to take tamoxifen because of the side effects, raloxifene seems to be a safer choice. "Although no drugs are without side effects, tamoxifen and raloxifene are vital options for women who are at increased risk of breast cancer and want to take action, said Dr. Leslie Ford, associate director for clinical research at the NCI's Division of Cancer Prevention. "For many women, raloxifene's benefits will outweigh its risks in a way that tamoxifen's benefits do not.

RELATED PROGRAMS

Copyright Healthology, Inc., an iVillage Company providing health information
Privacy Policy - Disclaimer - Editorial & Sponsorship Policy
We subscribe to the HONcode principles. Verify here

Bartlett Guild's Annual Art Show
Highlights and pictures of some the those that participated.

Profile: Dr. James Borden, General Surgeon
The continuing adventures of Juneau's newest surgeon...

The Killer Snore
His doctor asked the right questions...

Real Estate
Juneau Guide
This Week